{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:38Z","timestamp":1789469138302,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07130-w","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:15:15Z","timestamp":1781327715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-6 levels decrease following rituximab treatment but increase following tocilizumab treatment"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5296-7518","authenticated-orcid":false,"given":"Makoto","family":"Ide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"7130_CR1","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.blre.2023.101161","volume":"64","author":"E Lang","year":"2024","unstructured":"Lang E, van Rhee F (2024) Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances. Blood Rev 64:101161. https:\/\/doi.org\/10.1016\/j.blre.2023.101161","journal-title":"Blood Rev"},{"key":"7130_CR2","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1002\/ajh.27132","volume":"99","author":"NA Mango","year":"2024","unstructured":"Mango NA, Pierson SK, Sarmiento Bustamante M, Brandstadter JD, van Rhee F, Fajgenbaum DC (2024) Siltuximab administration results in spurious IL-6 elevation in peripheral blood. Am J Hematol 99:E15\u201318. https:\/\/doi.org\/10.1002\/ajh.27132","journal-title":"Am J Hematol"},{"key":"7130_CR3","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132:2115\u20132124. https:\/\/doi.org\/10.1182\/blood-2018-07-862334","journal-title":"Blood"},{"key":"7130_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00277-017-3111-x","volume":"96","author":"M Akiyama","year":"2017","unstructured":"Akiyama M, Yasuoka H, Takeuchi T (2017) Interleukin-6 in idiopathic multicentric Castleman\u2019s disease after long-term tocilizumab. Ann Hematol 96:2117\u20132119. https:\/\/doi.org\/10.1007\/s00277-017-3111-x","journal-title":"Ann Hematol"},{"key":"7130_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3960\/jslrt.53.69","volume":"53","author":"H Kawabata","year":"2013","unstructured":"Kawabata H, Kadowaki N, Nishikori M et al (2013) Clinical features and treatment of multicentric Castleman\u2019s disease: A retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematopathol 53:69\u201377. https:\/\/doi.org\/10.3960\/jslrt.53.69","journal-title":"J Clin Exp Hematopathol"},{"key":"7130_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.11406\/rinketsu.58.97","volume":"58","author":"K Yoshizaki","year":"2017","unstructured":"Yoshizaki K (2017) A reference guide for management of Castleman disease. Rinsho Ketsueki 58:97\u2013107. https:\/\/doi.org\/10.11406\/rinketsu.58.97","journal-title":"Rinsho Ketsueki"},{"key":"7130_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14397595.2017.1366093","volume":"28","author":"S Fujimoto","year":"2018","unstructured":"Fujimoto S, Koga T, Kawakami A et al (2018) Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. Mod Rheumatol 28:161\u2013167. https:\/\/doi.org\/10.1080\/14397595.2017.1366093","journal-title":"Mod Rheumatol"},{"key":"7130_CR8","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood.v98.12.3473","volume":"98","author":"M Corbellino","year":"2001","unstructured":"Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473\u20133475. https:\/\/doi.org\/10.1182\/blood.v98.12.3473","journal-title":"Blood"},{"key":"7130_CR9","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","volume":"25","author":"L G\u00e9rard","year":"2007","unstructured":"G\u00e9rard L, B\u00e9rezn\u00e9 A, Galicier L et al (2007) Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus-associated multicentric Castleman\u2019s disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25:3350\u20133356. https:\/\/doi.org\/10.1200\/JCO.2007.10.6732","journal-title":"J Clin Oncol"},{"issue":"1","key":"7130_CR10","doi-asserted-by":"publisher","first-page":"9378","DOI":"10.1182\/blood-2022-170360","volume":"140","author":"SK Pierson","year":"2022","unstructured":"Pierson SK, Sarmiento Bustamante M, Brandstadter JD et al (2022) Longitudinal, real-world data reveal treatment effectiveness in idiopathic multicentric Castleman disease and support current treatment guidelines. Blood 140(1):9378\u20139379. https:\/\/doi.org\/10.1182\/blood-2022-170360","journal-title":"Blood"},{"key":"7130_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2005.00570.x","volume":"76","author":"M Ide","year":"2006","unstructured":"Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T (2006) Long-term remission in HIV-negative patients with multicentric Castleman\u2019s disease using rituximab. Eur J Haematol 76:119\u2013123. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00570.x","journal-title":"Eur J Haematol"},{"key":"7130_CR12","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-018-3347-0","volume":"97","author":"Y Dong","year":"2018","unstructured":"Dong Y, Zhang L, Nong L et al (2018) Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Ann Hematol 97:1641\u20131647. https:\/\/doi.org\/10.1007\/s00277-018-3347-0","journal-title":"Ann Hematol"},{"key":"7130_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.bloodjournal7441360","volume":"74","author":"K Yoshizaki","year":"1989","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease. Blood 74:1360\u20131367. https:\/\/doi.org\/10.1182\/blood.V74.4.1360.bloodjournal7441360","journal-title":"Blood"},{"key":"7130_CR14","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood.2023021992","volume":"143","author":"JY Chan","year":"2024","unstructured":"Chan JY, Loh JW, Lim JQ et al (2024) Single-cell landscape of idiopathic multicentric Castleman disease in identical twins. Blood 143:1837\u20131844. https:\/\/doi.org\/10.1182\/blood.2023021992","journal-title":"Blood"},{"key":"7130_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajh.25554","volume":"94","author":"S Fujimoto","year":"2019","unstructured":"Fujimoto S, Sakai T, Kawabata H et al (2019) Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94:975\u2013983. https:\/\/doi.org\/10.1002\/ajh.25554","journal-title":"Am J Hematol"},{"key":"7130_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12185-020-03008-3","volume":"113","author":"S Fujimoto","year":"2021","unstructured":"Fujimoto S, Kawabata H, Sakai T et al (2021) Optimal treatments for TAFRO syndrome: A retrospective surveillance study in Japan. Int J Hematol 113:73\u201380. https:\/\/doi.org\/10.1007\/s12185-020-03008-3","journal-title":"Int J Hematol"},{"key":"7130_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood.V95.1.56.001k13_56_61","volume":"95","author":"N Nishimoto","year":"2000","unstructured":"Nishimoto N, Sasai M, Shima Y et al (2000) Improvement in Castleman\u2019s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56\u201361. https:\/\/doi.org\/10.1182\/blood.V95.1.56.001k13_56_61","journal-title":"Blood"},{"key":"7130_CR18","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627\u20132632. https:\/\/doi.org\/10.1182\/blood-2004-12-4602","journal-title":"Blood"},{"key":"7130_CR19","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964. https:\/\/doi.org\/10.1182\/blood-2008-05-155846","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07130-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07130-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07130-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:50Z","timestamp":1789465370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07130-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7130"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07130-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Takamatsu Red Cross Hospital (No. 24\u2009\u2212\u2009022), and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No personally identifiable data is included.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained in the form of an opt-out on the website.\n                      \n                      .","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"383"}}